-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on AbbVie, Raises Price Target to $260

Benzinga·07/13/2026 18:24:21
Listen to the news
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $230 to $260.